Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04034927
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:56.891326+00:00
Published At
2023-10-13T00:00:00+00:00
Record Updated At
2026-04-13
Results Posted At
2023-10-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Endometrioid Tumor", "Fallopian Tube High Grade Serous Adenocarcinoma", "Malignant Ovarian Endometrioid Tumor", "Ovarian High Grade Serous Adenocarcinoma", "Platinum-Sensitive Fallopian Tube Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Platinum-Sensitive Primary Peritoneal Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian Serous Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT04034927"
protocolSection.identificationModule.officialTitle
"A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-10-13"

Study condition terms

  • Fallopian Tube Endometrioid Tumor (protocolSection.conditionsModule.conditions)
  • Fallopian Tube High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Endometrioid Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Sensitive Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Sensitive Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Sensitive Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal High Grade Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.